Results in 37 samples tested for both MSI status and hMLH1 expression
| Hyperplasia (n=13) | Dysplasia (n=13) | Carcinoma (n=11) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient | S | L | H | hMLH1 | S | L | H | hMLH1 | S | L | H | hMLH1 | ||
| 1 | 4/5 | 1/5 | 0/5 | 0/5 | 2/6 | 2/6 | 2/62-150 | 4/6 | 0/2 | 0/2 | 2/22-151 | 2/2 | ||
| 2 | — | — | — | — | 0/1 | 0/1 | 1/12-152 | 1/1 | 1/2 | 1/2 | 0/2 | 0/2 | ||
| 3 | 8/8 | 0/8 | 0/8 | 0/8 | 4/5 | 1/5 | 0/5 | 2/5 | 1/1 | 0/1 | 0/1 | 0/1 | ||
| 4 | — | — | — | — | 0/1 | 0/1 | 1/1 | 1/1 | 1/6 | 1/6 | 4/6 | 4/6 | ||
S, stable, L, low, H, high (microsatellite instability (MSI) status); hMLH1, loss of protein by immunohistochemistry.
Mutated target genes in samples tested only from patient Nos 1–3 were as follows:
↵2-150 TGFβ-RII, IGF2R, BAX, MSH3, MSH6 in dysplasia contiguous with smaller cancer, MSH6 in dysplastic focus;
↵2-151 TGFβR-II, IGF2R, BAX, MSH3, MSH6 in smaller cancer, MSH6 in larger cancer;
↵2-152 BAX, MSH3.